Economic evaluation of the second-line regimen of liposome irinotecan (II) combined with 5-FU/LV versus placebo combined with 5-FU/LV for locally advanced or metastatic pancreatic ductal adenocarcinoma in China. [PDF]
PLoS ONEBackgroundThe cost-effectiveness of liposome irinotecan (II) (HR070803) in combination with 5-fluorouracil and leucovorin as a treatment for patients with locally advanced or metastatic pancreatic ductal adenocarcinoma offering a potential new standard ...
Jinlong Huang +5 more
doaj +2 more sources
Quimioterapia con fármacos nuevos en el cáncer de pulmón de célula no pequeña avanzado [PDF]
, 2004 [spa] El cáncer de pulmón es el cáncer más frecuente en todo el mundo. A principio de la década de los 90 aparecieron varios fármacos con una actividad prometedora en cáncer de pulmón de célula no pequeña (CPCNP). El núcleo de esta tesis doctoral son dos
Cardenal Alemany, Felipe
core +5 more sources
Hepatic ROS Mediated Macrophage Activation Is Responsible for Irinotecan Induced Liver Injury
Cells, 2022 Irinotecan is the first line chemotherapy drug used for treatment of metastatic colorectal cancer worldwide. There is increasing evidence suggesting that liver damage, including steatosis and steatohepatitis, can be caused during the treatment involving ...
Bohao Liu +7 more
doaj +1 more source
CPT: Pharmacometrics & Systems Pharmacology, 2021 Liposomal irinotecan is a liposomal formulation of irinotecan, which prolongs circulation of irinotecan and its active metabolite SN‐38. A population pharmacokinetic (PK) model was developed based on data from seven studies (N = 440).
Karl Brendel +10 more
doaj +1 more source
Establishment and Characterization of an Irinotecan-Resistant Human Colon Cancer Cell Line
Frontiers in Oncology, 2021 Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide. Irinotecan is widely used as a chemotherapeutic drug to treat CRC. However, the mechanisms of acquired resistance to irinotecan in CRC remain inconclusive.
Zhuo-Xun Wu +7 more
doaj +1 more source
Deciphering the Formulation-Dependent Neurotoxicity of Irinotecan: An Integrated Pharmacovigilance and Mechanistic Study. [PDF]
J Biochem Mol ToxicolIrinotecan is a key chemotherapeutic agent, but its neurotoxicity limits its utility. Observed differences in neurotoxicity between conventional and liposomal formulations are poorly characterized mechanistically.
Shen C, Ma W, Lu J, Tang Y, Cao W.
europepmc +2 more sources
Therapeutic Advances in Medical Oncology, 2021 Introduction: Liposomal irinotecan (nal-IRI) plus fluorouracil/leucovorin (5-FU/LV) has shown clinical benefit in patients with metastatic pancreatic adenocarcinoma (mPAC) who progressed on gemcitabine-based chemotherapy.
Kyunghye Bang +6 more
doaj +1 more source
Determination of Irinotecan enantiomer impurity in Irinotecan Hydrochloride API by using reverse-phase liquid chromatography [PDF]
, 2023 To evaluate and quantify Irinotecan (R-enantiomer) / Irinotecan related compound D in Irinotecan hydrochloride trihydrate API, a high stereo-specific liquid chromatography technique was developed and validated.
Srinivas P, Vijay +5 more
core +1 more source
Bevacizumab plus Irinotecan-Based Regimens in the Treatment of Metastatic Colorectal Cancer [PDF]
, 2010 Objectives: Bevacizumab is a monoclonal antibody that directly inhibits vascular endothelial growth factor, a key regulator of angiogenesis. Bevacizumab significantly improves progression-free and/or overall survival in metastatic colorectal cancer in ...
Volker Heinemann +3 more
core +1 more source
PLoS ONE, 2020 Irinotecan specifically targets topoisomerase I (topoI), and is used to treat various solid tumors, but only 13-32% of patients respond to the therapy.
Hiroya Matsuoka +11 more
doaj +1 more source